LONDON-- GlaxoSmithKline PLC (GSK.LN) Friday said it received U.S. Food and Drug Administration approval for a new self-injectable form of Benlysta, a treatment for the immune system disease systemic lupus erythematosus.

Glaxo also said Friday that it has submitted an EU filing for the use of its drug Relvar Ellipta in patients with Asthma.

Shares at 1300 GMT, down 2 pence, or 0.15%, at 1,623 pence valuing the company at GBP79.8 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

July 21, 2017 09:18 ET (13:18 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.